It is very uncertain whether summary of findings: pioglitazone monotherapy changes all‐cause mortality (N) compared with no intervention (very low certainty).

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
RR 0.85 [0.38, 1.91]
3 studies · 866 participants
Very low

Metformin vs diet and exercise or another antidiabetic drug

All‐cause mortality · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table for metformin plus intensive diet and exercise vs intensive diet and exercise

All‐cause mortality · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased… 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 450 participants
Very low

Acarbose vs placebo

All‐cause mortality · people at increased risk for developing type 2 diabetes

It is very uncertain whether acarbose changes all‐cause mortality compared with placebo (very low certainty).

1 finding from 1 review

Alpha‐glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in… 2018 · Cochrane Headline outcomes only
RR 0.98 [0.82, 1.18]
3 studies · 8069 participants
Very low

Acarbose vs no intervention

All‐cause mortality · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Alpha‐glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in… 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 171 participants
Very low

Short‐acting insulin analogues vs regular human insulin

All‐cause mortality

Short‐acting insulin analogues showed no clear difference in all‐cause mortality (N) compared with regular human insulin (moderate certainty).

1 finding from 1 review · compare the 2 reviews

Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes… 2018 · Cochrane Headline outcomes only
Peto OR 1.66 [0.41, 6.64]
6 studies · 2519 participants
Moderate

Adverse event outcomes for dietary combined with physical activity interventions vs usual care

All‐cause mortality · people at increased risk for developing type 2 diabetes

It is very uncertain whether diet plus physical activity changes all‐cause mortality compared with standard treatment (very low certainty).

1 finding from 1 review

Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications… 2017 · Cochrane Headline outcomes only
RR 1.12 [0.5, 2.5]
10 studies · 4099 participants
Very low

Physical activity vs usual care

All‐cause mortality · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications… 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 397 participants
Very low

Diet vs physical activity or standard treatment

All‐cause mortality · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 530 participants
Very low

Intervention not reported

All‐cause mortality · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 179 participants
Very low

Intervention not reported

All‐cause mortality · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2281 participants
Very low

Intervention not reported

All‐cause mortality · people at risk for the development of type 2 diabetes mellitus

1 finding from 1 review

Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons… 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 274 participants
Very low

Intervention not reported

All‐cause mortality · people at risk for the development of type 2 diabetes mellitus

1 finding from 1 review

Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons… 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9306 participants
Moderate